Rhythm Pharmaceuticals (RYTM) stock is in focus after Japan granted marketing authorization for IMCIVREE to treat acquired hypothalamic obesity, marking the first approved therapy for this rare condition in that market.
At a share price of $102.74, Rhythm Pharmaceuticals has recently seen momentum cool, with the 30 day share price return down 11.15% and the 7 day move also lower, even though the 90 day share price return is up 16.94% and the five year total shareholder return is very large.
Scan beyond Rhythm Pharmaceuticals and size up hand picked rare disease players with resilient balance sheets using our list of solid balance sheet and fundamentals (53 results) as a starting universe.
Rhythm Pharmaceuticals now trades at $102.74 while the range of estimated fair values points materially higher, so the gap between price and appraisal is wide. How does that spread frame the risk reward from here?
Most Popular Narrative: 23.3% Undervalued
Rhythm Pharmaceuticals last closed at $102.74, while the most followed narrative pegs fair value at $134. This sets up a sizeable implied upside that investors are trying to understand.
Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio. I rate RYTM a BUY, driven by expected double-digit revenue growth, a broader targeted-obesity portfolio, and stronger-than-expected patient uptake.
Read the complete narrative. Read the complete narrative.
Investors may want to understand why this narrative sees so much headroom from here. It leans heavily on rapid revenue expansion, a widening rare disease footprint, and a future earnings profile that looks very different to today. The key assumptions sit inside those growth curves and margin expectations, not in short term market swings.
Result: Fair Value of $134 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Rhythm Pharmaceuticals still faces key risks, including clinical or regulatory setbacks for IMCIVREE and slower than expected uptake across its rare disease indications.
Find out about the key risks to this Rhythm Pharmaceuticals narrative.
Another View On Rhythm Pharmaceuticals’ Valuation
The user narrative suggests Rhythm Pharmaceuticals is trading below a $134 fair value. However, on a simple P/S yardstick the stock appears demanding at 29.5x, which is more than double the US biotech average of 13.2x, above peers at 9.5x, and ahead of a 17.3x fair ratio. How comfortable are you paying that kind of premium multiple for this story?
See what the numbers indicate about this price in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
After weighing bullish narratives and premium multiples around Rhythm Pharmaceuticals, you should test the story against the data yourself and move quickly if you feel conviction. To see what investors are highlighting on the upside, take a closer look at the 3 key rewards.
Looking for more investment ideas beyond Rhythm Pharmaceuticals?
If Rhythm Pharmaceuticals has your attention, do not stop here. A few minutes spent widening your watchlist today could shape the ideas you consider next.
- Spot potential mispricings early by scanning our curated pool of 47 high quality undervalued stocks that combine quality fundamentals with attractive tags.
- Strengthen your defense by checking companies in the 80 resilient stocks with low risk scores that aim to keep balance sheet and risk scores front of mind.
- Get ahead of the crowd by reviewing 17 high quality undiscovered gems before they appear on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com